

Claims

1. A compound according to formula **3** below:





3


wherein:






is independently selected from the group comprising:



and ;



is independently selected from the group comprising:



,  and ;



R^1 is independently at each occurrence H or Ac;



R^2 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;

R^5 is independently at each occurrence selected from the group comprising: H, Ac, and $C_{1\text{-}4}$ alkyl;

provided always that the compound is not sitagliptin.



2. The compound of claim 1, wherein  is .

3. The compound of claim 1, wherein  is .

4. The compound of any preceding claim, wherein  is .

5. The compound of claim 4, wherein R^2 is H.

6. The compound of claim 4, wherein R^2 is methyl, ethyl, propyl, isopropyl, butyl or tert-butyl.

7. The compound of claim 1 or claim 2, wherein  is .

8. The compound of any one of claims 1 to 7 for use as a medicament.

9. A pharmaceutical composition comprising the compound of any of claims 1 to 7, together with one or more pharmaceutical excipients.


10. An oral dosage form comprising the compound of any of claims 1 to 7, together with one or more pharmaceutical excipients.

11. An intravenous dosage form comprising the compound of any of claims 1 to 7, together with one or more pharmaceutical excipients.

12. The compound of any one of claims 1 to 7, for use in the treatment of diabetes.


Claims


1. A compound according to formula **3** below:







3a

wherein either:

A)  is:

;

 is independently selected from the group comprising:


,  and ;



R^1 is independently at each occurrence H or Ac;


R^2 is independently at each occurrence C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;




R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;

or

B)  is independently selected from the group comprising:

 and ;



 is independently selected from the group comprising:





and ;



R^1 is Ac;

R^2 is independently at each occurrence C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;



R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl.

2. The compound of claim 1, wherein  is .


3. The compound of claim 1, wherein  is .

4. The compound of any preceding claim, wherein  is .

5. The compound of claim 4, wherein R^2 is methyl, ethyl, propyl, isopropyl, butyl or tert-butyl.



6. The compound of claim 1 or claim 2, wherein  is .


7. A compound of formula **3b** for use as a medicament:






3b

wherein either:

A)  is ;


is independently selected from the group comprising:



,

and

;



R^1 is independently at each occurrence H or Ac;


R^2 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;




R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;

or

B)  is independently selected from the group comprising:


and

;


is independently selected from the group comprising:



,

and

;

R^1 is Ac;

R^2 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;



R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl.


8. A pharmaceutical composition comprising one or more pharmaceutical excipients with a compound of formula **3b**:






3b

wherein either:

A)  is ;

 is independently selected from the group comprising:


,  and ;



R^1 is independently at each occurrence H or Ac;


R^2 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;




R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;

or

B)  is independently selected from the group comprising:

 and ;

 is independently selected from the group comprising:


,  and ;

R^1 is Ac;

R^2 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;



R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl.


9. The compound of formula 3b, for use in the treatment of diabetes:






3b

wherein either:

A)  is  ;

 is independently selected from the group comprising:


 ,  and  ;



R^1 is independently at each occurrence H or Ac;


R^2 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;




R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;

or

B)  is independently selected from the group comprising:

 and  ;

 is independently selected from the group comprising:

 ,  and  ;

R^1 is Ac;

R^2 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl;

R^3 is independently at each occurrence H, C_1 alkyl, C_2 alkyl, C_3 alkyl or C_4 alkyl.